The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: A retrospective case series of 10 patients

Journal of Infection and Chemotherapy

Volumn 19, Issue 1, 2013, Pages 42-49

  Lin, Jennifer C ^a   Aung, Gregory ^b   Thomas, Amy ^c   Jahng, Maximillian ^d   Johns, Scott ^b   Fierer, Joshua ^a,b,e  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF THE PACIFIC   (United States)

^d New Mexico Veterans Affairs (VA) Healthcare System   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bacteremia; Ceftaroline; Endocarditis; Methicillin resistant Staphylococcus aureus (MRSA); Osteomyelitis

Indexed keywords

CEFTAROLINE FOSAMIL; CLINDAMYCIN; COTRIMOXAZOLE; CREATININE; DAPTOMYCIN; GENTAMICIN; LINEZOLID; MINOCYCLINE; PIPERACILLIN; RIFAMPICIN; TICARCILLIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; ARTIFICIAL HEART PACEMAKER; BACTEREMIA; BACTERIAL ARTHRITIS; BACTERIAL ENDOCARDITIS; BLOOD CULTURE; BRONCHOPLEURAL FISTULA; CATHETER INFECTION; CATHETER REMOVAL; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CREATININE CLEARANCE; DEATH; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EOSINOPHILIA; FEMALE; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MALE; MEDICAL RECORD REVIEW; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; OSTEOMYELITIS; PALLIATIVE THERAPY; PLEURA EMPYEMA; PNEUMONIA; PROSTHESIS INFECTION; PRURITUS; PSOAS ABSCESS; PYOMYOSITIS; THORACOCENTESIS; UNITED STATES; URTICARIA;

EID: 84874107604     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-012-0449-9     Document Type: Article

References (15)

1. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003;36(1):53-9.
2. Whitby M, McLaws ML, Berry G. Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis. Med J Aust. 2001;175(5):264-7.
3. Stryjewski ME, Szczech LA, Benjamin DK Jr, Inrig JK, Kanafani ZA, Engemann JJ, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis. 2007;44(2):190-6.
4. Chang FY, Peacock JE Jr, Musher DM, Triplett P, MacDonald BB, Mylotte JM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltim). 2003;82(5):333-9.
5. Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653-65.
6. Kosowska-Shick K, McGhee PL, Appelbaum PC. Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2010;54(5):1670-7.
7. Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T (2010) CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 65(suppl 4):iv41-iv51
8. Wilcox MH, Corey GR, Talbot GH, Thye D, Friedland D, Baculik T (2010) CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 65(suppl 4):iv53-iv65.
9. File TM Jr, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, et al (2011) FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011;66(suppl 3):iii19-iii32.
10. Low DE, File TM, Jr., Eckburg PB, Talbot GH, David Friedland H, Lee J, et al. (2011) FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 66(suppl 3):iii33-iii44.
11. Ho TT, Cadena J, Childs LM, Gonzalez-Velez M, Lewis JS 2nd (2012) Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother 67(5):1267-1270
12. Steed ME, Rybak MJ. Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens. Pharmacotherapy. 2010;30(4):375-89.
13. Laudano JB (2011) Ceftaroline fosamil: a new broad-spectrum cephalosporin. J Antimicrob Chemother 2011;66(suppl 3):iii11-iii18
14. Laboratories F (2010) Teflaro (ceftaroline fosamil) package insert. Forest Laboratories, St. Louis, MO
15. Jones RN, Mendes RE, Sader HS (2010) Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study. J Antimicrob Chemother 65(suppl 4):iv17-iv31.